Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01516086 · ClinicalTrials.gov registry record · Phase 2
A 12-Week Study in Adult Subjects With Asthma
A Phase 2 study, sponsored by Dey.
- Completed
- Registry status
- Phase 2
- Development phase
- 498
- Enrollment target
NCT01516086: Completed Phase 2 study, sponsored by Dey.
NCT01516086 is a Phase 2 study that has completed, run by Dey. The registered enrollment target is 498 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (274% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01516086, a Phase 2 study, has completed, sponsored by Dey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 498 participants
- Enrollment target
Study Summary
This will be a multi-center, randomized, placebo controlled parallel-group study to Replicate Efficacy of Nebulized Fluticasone Propionate (FP) in Adult Subjects with Partly Controlled and Uncontrolled Asthma. Individual participation will be approximately 16 weeks, including 12 weeks of double-blind treatment.
Interventions
- DRUG Fluticasone Propionate (FP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 498 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
What the finished NCT01516086 record still lists
NCT01516086 is an interventional study that assigns participants to a tested intervention. The registered 498 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (274% higher).
The record links to 0 conditions, and to 1 intervention - of which Fluticasone Propionate (FP) is the first listed.
NCT01516086 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01516086 about?
NCT01516086 is a clinical study titled "A 12-Week Study in Adult Subjects With Asthma". This will be a multi-center, randomized, placebo controlled parallel-group study to Replicate Efficacy of Nebulized Fluticasone Propionate (FP) in Adult Subjects with Partly Controlled and Uncontrolled Asthma. Individual participation will be approximately 16 weeks, including 12 weeks of double-blin...
What is the current status of trial NCT01516086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 498 participants. The study started on 2012-03. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01516086?
The interventions under investigation include: Fluticasone Propionate (FP) (DRUG).
Who is sponsoring clinical trial NCT01516086?
This trial is sponsored by Dey, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01516086's enrollment target sits among peer trials
498 74th of 2000 higher than 1,927 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04137900 · 499 participants · Phase 1
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
- NCT06733480 · 499 participants · NA
Innovating Physical Therapy: A Pilot Study on Band Connect's Impact on Compliance, Satisfaction, and Revenue
- NCT03175224 · 497 participants · Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- NCT05301816 · 497 participants · NA
PDN Post Market, Multicenter, Prospective, Global Clinical Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia